Advanced search    

Search: authors:"Henry Chrystyn"

11 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Study of the Emitted Dose After Two Separate Inhalations at Different Inhalation Flow Rates and Volumes and an Assessment of Aerodynamic Characteristics of Indacaterol Onbrez Breezhaler® 150 and 300 μg

amount, PSD particle size distribution COMPLIANCE WITH ETHICAL STANDARDS Conflict of Interest Henry Chrystyn has no shares in any pharmaceutical companies. He has received sponsorship to carry out

Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study

Background Spiromax® is a novel dry-powder inhaler containing formulations of budesonide plus formoterol (BF). The device is intended to provide dose equivalence with enhanced user-friendliness compared to BF Turbuhaler® in asthma and chronic obstructive pulmonary disease (COPD). The present study was performed to compare inhalation parameters with empty versions of the two...

Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study

Spiromax® is a novel dry-powder inhaler containing formulations of budesonide plus formoterol (BF). The device is intended to provide dose equivalence with enhanced user-friendliness compared to BF Turbuhaler® in asthma and chronic obstructive pulmonary disease (COPD). The present study was performed to compare inhalation parameters with empty versions of the two devices, and to...

An Open-Label Investigation of the Pharmacokinetics and Tolerability of Oral Cysteamine in Adults with Cystic Fibrosis

Background and Objective Cysteamine is licensed for use in nephropathic cystinosis but preclinical data suggest a role in managing cystic fibrosis (CF). This study aimed to determine whether oral cysteamine is absorbed in adult CF patients and enters the bronchial secretions. Tolerability outcomes were also explored. Methods Patients ≥18 years of age, weighing >50 kg with stable...

A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices

with other inhaler devices Job van der Palen 3 4 Mike Thomas 5 6 Henry Chrystyn 7 Raj K Sharma 8 Paul DLPM van der Valk 3 Martijn Goosens 9 Tom Wilkinson 10 Carol Stonham 11 Anoop J Chauhan 12 Varsha ... participated and also the GSK study team. The external experts who participated in the development of the error checklist were Job van der Palen, Mike Thomas and Henry Chrystyn. CONTRIBUTIONS JvdP, MT, HC

Comparison of serious inhaler technique errors made by device-naïve patients using three different dry powder inhalers: a randomised, crossover, open-label study

Background Serious inhaler technique errors can impair drug delivery to the lungs. This randomised, crossover, open-label study evaluated the proportion of patients making predefined serious errors with Pulmojet compared with Diskus and Turbohaler dry powder inhalers. Methods Patients ≥18 years old with asthma and/or COPD who were current users of an inhaler but naïve to the...

Preference, satisfaction and critical errors with Genuair and Breezhaler inhalers in patients with COPD: a randomised, cross-over, multicentre study

Background:The specific attributes of inhaler devices can influence patient use, satisfaction and treatment compliance, and may ultimately impact on clinical outcomes in patients with chronic obstructive pulmonary disease (COPD).Aims:To assess patient preference, satisfaction and critical inhaler technique errors with Genuair (a multidose inhaler) and Breezhaler (a single-dose...

Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial

controlled trial Graham Devereux 0 Seonaidh Cotton 2 Peter Barnes 1 Andrew Briggs 7 Graham Burns 6 Rekha Chaudhuri 5 Henry Chrystyn 4 Lisa Davies 9 Anthony De Soyza 8 Shona Fielding 3 Simon Gompertz 12 John

Asthma control in patients receiving inhaled corticosteroid and long-acting beta2-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation

involvement with drafting of the paper. All authors read and approved the final manuscript. Conflict of interest declaration Henry Chrystyn has no shares in any pharmaceutical companies. He has received

Airmax™

Airmax™ 1 A Viewpoint by Henry Chrystyn 0 University of Bradford, Bradford , England - A consistent and reliable emitted dose that is not affected by the patient’s inhalation technique is an

Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control

Background As more inhaled corticosteroid (ICS) devices become available, there may be pressure for health-care providers to switch patients with asthma to cheaper inhaler devices. Our objective was to evaluate impact on asthma control of inhaler device switching without an accompanying consultation in general practice. Methods This 2-year retrospective matched cohort study used...